drugset / Trial / NCT05015426
Gamma Delta T-cell Infusion for AML at High Risk of Relapse After Allo HCT
Phase 1
Active not recruiting
20 enrolled
H. Lee Moffitt Cancer Center and Research Institute
Florida Department of Health · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The purposes of the study are to determine the maximum tolerated dose (MTD) and effectiveness of Artificial Antigen Presenting Cell (AAPC)-expanded donor T-cells administered as a single infusion after an allogeneic hematopoietic cell transplant (alloHCT) to treat patients with Acute Myeloid Leukemia (AML).
Timeline
- Start
- 2022-03-21
- Primary completion
- 2025-08-30
- Completion
- 2026-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Gamma Delta T-Cell | Unknown | 1e+06 cells/kg | Other |
| Subject | Gamma Delta T-Cell | Unknown | 5e+06 cells/kg | Other |
| Subject | Gamma Delta T-Cell | Unknown | 2.5e+07 cells/kg | Other |
| Subject | Gamma Delta T-Cell | Unknown | 1e+08 cells/kg | Other |